RNA Analytical/Quality Videos

  1. CMC Innovations Worth Watching In The RNA-LNP Space 12/4/2024

    Sanofi’s Sumit Luthra shares several of the analytical and manufacturing innovations/improvements he’s watching and waiting for that will improve our knowledge of LNP composition, structure, function, and quality.

  2. How "Successful" Are Our mRNA-LNP Outsourcing Partnerships Today? 2/10/2025

    In this snippet, panelist Alex Aust (with the help of several live attendee commenters) tackles a particularly tricky question: Are our outsourcing partnerships producing high quality products today, and what are the most common root causes of batch failures?

  3. Outgrowing Legacy Methods: mRNA's Transition from Protein Paradigms 6/9/2026

    AbbVie’s Elaine Peters, Sanofi’s Philippe Talaga, and Tessera’s Ilya Shestopalov highlight the technical limitations of legacy analytical methods in evaluating and measuring mRNA-LNP concentration, structure, purity, integrity, and impurities.

  4. The Make-or-Break Quality Attributes of Plasmid DNA 10/15/2025

    We all know that plasmid quality is foundational in dictating the quality of the final mRNA drug substance. In this clip homing in on upstream process considerations, speakers Stu Sundseth (Tune Therapeutics), Marc Wolfgang (Sail Biomedicines), and Christian Dohmen (Ethris) outline some of the most important CQAs for plasmids and the impact they can have on the resulting quality of the mRNA drug substance for linear mRNA. 

  5. A&M STABTEST Shares QC Analysis Of Oligo Therapeutics 9/20/2022

    Explore best practices for developing a QC method for identification and impurity analysis of oligonucleotides, as well as tips on mitigating risk by using compliant instrumentation and software.

  6. Why We Still Haven't Solved mRNA Scale-Up 10/15/2025

    While we can make lots of mRNA at a smaller scale, when it comes to scaling up to kg quantities of mRNA, our current batch processes leave a lot to be desired. Together, Stu Sundseth of Tune Therapeutics and Christian Dohmen of Ethris unpack the biggest barriers to scaling IVT to achieve the desired yield and quality of mRNA, offering their take on how the field is innovating to overcome these issues. 

  7. Customized mRNA Processing For Improved Therapy Development And Manufacturing 2/13/2025

    Optimize mRNA development by learning key strategies for process refinement, critical component identification, and in-process analytics to enhance therapeutic production.

  8. The Current State of pDNA Manufacturing Platforms for mRNA Production 10/29/2026

    In this Advancing RNA Live clip, Sanofi’s Nicolas Chaudet and Tune Therapeutics’ Tyler Goodwin share their perspectives on the current strengths and weaknesses of outsourced plasmid production. The discussion also homes in on the most important pDNA supplier capabilities mRNA producers should be keeping in mind as they select/work with partners. 

  9. Sustainable Vaccine Manufacturing: Securing The Future Of Global Health 7/22/2025

    Explore how next-gen technologies, from mRNA platforms to digital tools, are transforming vaccine manufacturing to make it more sustainable, flexible, and accessible.

  10. Beyond Cas9: How Diverse Nucleases are Redefining gRNA Design 4/29/2026

    As CRISPR technology evolves beyond the original Cas9, gRNAs are transitioning from simple targeting tools into highly engineered, complex molecules. In this Advancing RNA Live segment, speakers April Sena, Max De Long, and Venkat Krishnamurthy discuss how the rise of diverse nucleases — including prime editors — is impacting gRNA synthesis and purity.